By analyzing existing technical and fundamental indicators between Organigram Hlds and Powerbridge, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Powerbridge with a short position in Organigram Hlds. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Organigram Hlds has an asset utilization ratio of 25.67 percent. This implies that the company is making $0.26 for each dollar of assets. An increasing asset utilization means that Organigram Hlds is more efficient with each dollar of assets it utilizes for everyday operations.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in OrganiGram Holdings. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on OrganiGram Holdings, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
How important is OrganiGram Holdings's Liquidity
OrganiGram Holdings
financial leverage refers to using borrowed capital as a funding source to finance OrganiGram Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. OrganiGram Holdings financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to OrganiGram Holdings' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of OrganiGram Holdings' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between OrganiGram Holdings's total debt and its cash.
OrganiGram Holdings Gross Profit
OrganiGram Holdings Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing OrganiGram Holdings previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show OrganiGram Holdings Gross Profit growth over the last 10 years. Please check OrganiGram Holdings'
gross profit and other
fundamental indicators for more details.
What is driving OrganiGram Holdings Investor Appetite?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Let me now analyze Organigram Hlds revenue. Based on the latest financial disclosure, Organigram Hlds reported 107.4
M of revenue. This is 98.59% lower than that of the Healthcare sector and significantly higher than that of the
Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 98.86% higher than that of Organigram Hlds. As for Powerbridge Technologies we see revenue of 25.85
M, which is much higher than that of the Drug Manufacturers—Specialty & Generic
| Organigram | 107.4 Million |
| Sector | 0.0 |
| Powerbridge | 25.85 Million |
Organigram showing occurrence of lower volatility
Organigram Hlds current variance boosts over 21.49. Organigram Hlds exhibits very low volatility with skewness of 0.16 and kurtosis of -0.35. However, we advise investors to further study Organigram Hlds technical indicators to make sure all market info is available and is reliable. Organigram Hlds is a potential penny stock. Although Organigram Hlds may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Organigram Hlds. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Organigram instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Bottom Line On Organigram Hlds
While few other entities within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Organigram Hlds may offer a potential longer-term growth to stockholders. The inconsistency in the assessment between current Organigram valuation and our trade advice on Organigram Hlds is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Organigram Hlds.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of OrganiGram Holdings. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
